Correlation Between Sartorius Stedim and Integragen

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Sartorius Stedim and Integragen at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sartorius Stedim and Integragen into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Sartorius Stedim Biotech and Integragen, you can compare the effects of market volatilities on Sartorius Stedim and Integragen and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sartorius Stedim with a short position of Integragen. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sartorius Stedim and Integragen.

Diversification Opportunities for Sartorius Stedim and Integragen

0.21
  Correlation Coefficient

Modest diversification

The 3 months correlation between Sartorius and Integragen is 0.21. Overlapping area represents the amount of risk that can be diversified away by holding Sartorius Stedim Biotech and Integragen in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Integragen and Sartorius Stedim is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sartorius Stedim Biotech are associated (or correlated) with Integragen. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Integragen has no effect on the direction of Sartorius Stedim i.e., Sartorius Stedim and Integragen go up and down completely randomly.

Pair Corralation between Sartorius Stedim and Integragen

Assuming the 90 days trading horizon Sartorius Stedim Biotech is expected to generate 0.65 times more return on investment than Integragen. However, Sartorius Stedim Biotech is 1.55 times less risky than Integragen. It trades about -0.11 of its potential returns per unit of risk. Integragen is currently generating about -0.21 per unit of risk. If you would invest  19,075  in Sartorius Stedim Biotech on August 28, 2024 and sell it today you would lose (1,165) from holding Sartorius Stedim Biotech or give up 6.11% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Sartorius Stedim Biotech  vs.  Integragen

 Performance 
       Timeline  
Sartorius Stedim Biotech 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Sartorius Stedim Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong primary indicators, Sartorius Stedim is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.
Integragen 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Integragen has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Sartorius Stedim and Integragen Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Sartorius Stedim and Integragen

The main advantage of trading using opposite Sartorius Stedim and Integragen positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sartorius Stedim position performs unexpectedly, Integragen can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Integragen will offset losses from the drop in Integragen's long position.
The idea behind Sartorius Stedim Biotech and Integragen pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Other Complementary Tools

Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites